Mostrando 5 resultados de: 5
Subtipo de publicación
Article(5)
Publisher
Circulation(2)
Journal of the American College of Cardiology(1)
New England Journal of Medicine(1)
The Lancet Diabetes and Endocrinology(1)
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
ArticleAbstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoBPalabras claves:acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitorsAutores:Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.Fuentes:scopusAlirocumab and cardiovascular outcomes after acute coronary syndrome
ArticleAbstract: BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemicPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Ducrocq G., Eapen Z., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Quintero K., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valdovinos P.C.M., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:scopusEffects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ArticleAbstract: Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovasculPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Colhoun H.M., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., DIaz R., Dilic M., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Loizeau V., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ArticleAbstract: Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for mPalabras claves:acute coronary syndrome, lipoprotein(a), low-density lipoprotein cholesterol, PCSK9 inhibitorAutores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Scemama M., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusRisk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
ArticleAbstract: Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapPalabras claves:acute coronary syndrome, alirocumab, dyslipidemias, GUIDELINEAutores:Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., DIaz R., Goodman S.G., Harrington R.A., Jukema J.W., Li Q.H., Lopes R.D., Louie M.J., Moriarty P.M., PATRICIO LOPEZ -JARAMILLO, Roe M.T., Schwartz G.G., Steg P.G., Szarek M., Vogel R., White H.D., Zeiher A.M.Fuentes:googlescopus